
Dendreon Corporation / Nasdaq: DNDN
View 1 year chart below to see when DNDN went from $5 to $25 per share.
INVESTORS MAY HAVE CHANCE FOR 500% GAIN AGAIN
Research corporate news archives to discover why DNDN exploded in the first place.
JANUARY 15, 2008: Dendreon Receives European Patent Covering PROVENGE® and Company's ACI Platform Technology
We believe that Dendreon Corporation (NASDAQ: DNDN) will utimately receive FDA approval for Provenge® within the next 12 to 18 months.
Aggressive investors may want to consider 2009 and 2010 Call Options.
the OTC Money Group